Highlights Carna Biosciences, Inc.

Equities

4572

JP3220550002

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-07-16 am EDT			5-day change	1st Jan Change
408 ^JPY	+0.49%		+8.80%	-21.84%

May. 31	Carna Biosciences, Inc. announced that it has received ¥362.07 million in funding from Athos Capital Limited	CI
May. 15	Carna Biosciences, Inc. announced that it expects to receive ¥362.07 million in funding from Athos Capital Limited	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fresh Tracks Therapeutics, Inc. and Carna Biosciences, Inc. Enters into Termination of License Agreement	Mar. 07	CI
Carna Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Carna Biosciences, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022	22-05-09	CI
Brickell Biotech Obtains Exclusive Rights to Carna Biosciences' Inhibitor Portfolio Targeting Inflammatory Diseases	22-02-02	MT
Brickell Biotech, Inc. Enters into an Exclusive License Agreement with Carna Biosciences, Inc	22-02-02	CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021	21-08-05	CI
Carna Biosciences, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2021	21-08-05	CI
Carna Biosciences, Inc. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2020	21-02-12	CI
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020	21-02-12	CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2020	20-11-08	CI
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020	20-11-08	CI
Carna Biosciences, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2020	20-05-12	CI
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2020	20-05-12	CI
Carna Biosciences, Inc. Announces Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2019; Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020	20-02-07	CI
Carna Biosciences, Inc. Provides Earnings Forecast for the Fiscal Year Ending December 31, 2019	20-01-09	CI
Open Orphan Signs Contract with Carna Bioscience	19-11-18	CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2019; Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2019	19-11-07	CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2019; Provides Consolidated Earnings Guidance for the Year Ending December 31, 2019	19-08-12	CI
Gilead Sciences, Inc. and Carna Biosciences Announce Research and Development Collaboration to Develop Novel Immuno-Oncology Therapies	19-06-24	CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2019; Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2019	19-05-13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Carna Biosciences, Inc.

Equities

4572

JP3220550002

Highlights

Filters